SNCA and Parkinson disease: The benzimidazole NAB2 has demonstrated efficacy in rescuing α-synuclein-associated trafficking defects, particularly in the context of early onset Parkinsons disease, and acts in a Nedd4-dependent manner (Hatstat et al. 2021) (Table 1).